CIC
ALLO icon

Cornercap Investment Counsel’s Allogene Therapeutics ALLO Stock Holding History

Cornercap Investment Counsel’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-28,533
Closed -$79.9K – 467
2024
Q3 		$79.9K Sell
28,533
-34,937
-55% -$93.1K 0.02% 492
2024
Q2 		$148K Sell
63,470
-633
-1% -$1.87K 0.02% 557
2024
Q1 		$287K Buy
64,103
+3,469
+6% +$14.5K 0.04% 522
2023
Q4 		$195K Buy
+60,634
New +$172K 0.03% 534

Other funds holding ALLO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Cornercap Investment Counsel's ALLO Position: Q4 2024 in Review

Cornercap Investment Counsel sold out of Allogene Therapeutics (ALLO) in Q4 2024, closing a stake of 28,533 shares — an estimated $79.9K sold.

Cornercap Investment Counsel first reported a position in ALLO in Q4 2023 and held it in 4 quarters. The position peaked at $287K in Q1 2024. 174 funds tracked by Wall St. Rank hold ALLO as of Q4 2024.

  • Cornercap Investment Counsel reported no remaining Allogene Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Cornercap Investment Counsel sold 28,533 Allogene Therapeutics shares in Q4 2024, an estimated $79.9K.
  • Cornercap Investment Counsel first reported a position in Allogene Therapeutics in Q4 2023 and held it in 4 quarters.
  • Cornercap Investment Counsel's Allogene Therapeutics position peaked at $287K in Q1 2024.
  • 174 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q4 2024.

Based on Cornercap Investment Counsel's 13F filing for Q4 2024, filed 12 Feb 2025.